Search clinical trials for: Symlin (pramlintide)

Total 108 results

University of Colorado, Denver
Amylin Pharmaceuticals, LLC.

Completed

Pramlintide in Adolescents With Type 1 Diabetes

Type 1 Diabetes

United States
University of Maryland, Baltimore
Amylin Pharmaceuticals, LLC.

Withdrawn

Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

Type 2 Diabetes
AstraZeneca

Completed

Evaluation of the Bioavailability of Pramlintide

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Boston University
National Institute on Aging (NIA)

Recruiting

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease (DTAD)

Alzheimer Disease | Mild Cognitive Impairment

United States
AstraZeneca

Completed

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
AstraZeneca

Completed

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
AstraZeneca

Completed

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

Obesity

United States
H. Lee Moffitt Cancer Center and Research Institute

Withdrawn

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

Cutaneous Squamous Cell Carcinoma

United States
AstraZeneca

Completed

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Obesity

United States
AstraZeneca

Completed

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Obesity | Overweight

United States
Joslin Diabetes Center
Bristol-Myers Squibb

Completed

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Hypoglycemia | Evidence of Previous Gastric Surgery

United States
AstraZeneca

Completed

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

Obesity | Overweight

United States
Baylor College of Medicine

Completed

Continuous Subcutaneous Infusion of Pramlintide and Insulin

Type 1 Diabetes

United States
Oregon Health and Science University

Active, not recruiting

A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

Obesity

United States
University of Texas Southwestern Medical Center

Withdrawn

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

Type 1 Diabetes

United States
Danish Headache Center

Completed

Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients

Migraine Without Aura

Denmark
AstraZeneca
Juvenile Diabetes Research Foundation

Completed

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Baylor College of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Completed

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes (T2DM)

Type 2 Diabetes

United States
University Diabetes & Endocrine Consultants
Amylin Pharmaceuticals, LLC.

Completed

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

IDDM

United States
University of Virginia
The Paul Manning Foundation

Terminated

Pramlintide Combined With Model Predictive Control Algorithm (ALM002)

Type 1 Diabetes Mellitus

United States
AstraZeneca

Completed

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Obesity

United States
Montefiore Medical Center
Amylin Pharmaceuticals, LLC.

Completed

Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Ludwig-Maximilians - University of Munich
University of Rochester

Completed

Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide

Type 1 Diabetes
AstraZeneca

Completed

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Obesity | Overweight

United States
Albert Einstein College of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

Type 1 Diabetes

United States
University of Texas Southwestern Medical Center
Amylin Pharmaceuticals, LLC.

Completed

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

Diabetes | Schizophrenia | Schizoaffective Disorder | Weight Gain

United States
Cheryl Rosenfeld, DO
Amylin Pharmaceuticals, LLC.

Unknown

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
AstraZeneca
Takeda Pharmaceuticals North America, Inc.

Terminated

A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

Obesity

United States
Diabetes Care Center
Amylin Pharmaceuticals, LLC.

Completed

The Effect of Pramlintide on Meal Time Insulin Bolus

Type 1 Diabetes
AstraZeneca

Completed

Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

Diabetes Mellitus, Non-Insulin-Dependent

United States
AstraZeneca

Completed

A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
AstraZeneca

Completed

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Obesity | Overweight

United States
AstraZeneca

Completed

Evaluation of the Effect of Pramlintide on Satiety and Food Intake

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Australia
AstraZeneca

Completed

Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
AstraZeneca
Juvenile Diabetes Research Foundation

Completed

Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

Type 1 Diabetes

United States
University of Virginia
DexCom, Inc.; Tandem Diabetes Care, Inc.

Completed

Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Xeris Pharmaceuticals

Completed

Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

Diabetes Mellitus, Type 1 | Insulin-dependent Diabetes Mellitus

United States
AstraZeneca

Completed

Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

Diabetes Mellitus, Type 1

United States
McGill University
Juvenile Diabetes Research Foundation

Completed

Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

Type 1 Diabetes | Type 1 Diabetes Mellitus | Hyperglycemia, Postprandial

Canada
McGill University
Juvenile Diabetes Research Foundation

Completed

Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement

Type 1 Diabetes Mellitus

Canada
Baylor College of Medicine

Completed

The Role of Amylin and Glucagon in T1DM

Type 1 Diabetes

United States
Baylor College of Medicine

Completed

The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes

Type 1 Diabetes

United States
University of Colorado, Denver
Amylin Pharmaceuticals, LLC.

Withdrawn

Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

Diabetes Mellitus

United States
McGill University
Canadian Institutes of Health Research (CIHR)

Recruiting

Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Type 1 Diabetes | Postprandial Hyperglycemia

Canada
University Hospital, Basel, Switzerland
Hoffmann-La Roche

Completed

Scan-rescan Reproducibility of Myelin Sensitive MRI Techniques

Myelin Integrity

Switzerland
MMI Spa

Recruiting

PRIMO Post-Market Clinical Follow Up Study (PRIMO)

Open Surgery | Blood Vessels, Lymphatic Ducts and Nerves | Free Flaps

Spain, Switzerland, Italy, Belgium, Austria, Germany
Jessa Hospital

Terminated

Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR

Covid-19 | SARS-CoV-2 | Diagnosis | Polymerase Chain Reaction

Belgium
Filip Krag Knop

Recruiting

The Role of Amylin in Bone Metabolism (AmyBone)

Type 1 Diabetes | Bone Diseases, Metabolic

Denmark

Search clinical trials for: Symlin (pramlintide)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations